OakChart

PMV Pharmaceuticals Inc

PMVPHealthcare·Biotechnology·USA·Micro·NASD·Nov 11 • 3:59 PM ET

1.26+0.04 (3.28%)
2026-11-11 22:15 CET
Market cap
92.13 USD m
Revenue, TTM
0.00 USD m
Net income, TTM
-88.53 USD m
Free cash flow, TTM
-69.64 USD m
EPS diluted, TTM
-1.53
P/E
-
Compare

Price

PMVP against its 20, 50 and 200-day averages
2050200beatmiss
1.001.201.401.601.803.4M6.8MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26PMVPclose 1.2620-day 1.2950-day 1.39200-day 1.311.2652w high52w low

34.0% under the 52-week high of 1.91 on 1 Oct 2026. 52-week low 1.02 on 5 Feb 2026. Last 15 sessions, 30.9% high to low

Volume 0.23× normal · the line is the 50-bar volume average

Profile

PMVP
52-week range, 27% of the way up
1.021.91

PMV Pharmaceuticals, Inc. is a precision oncology company, which engages in the discovery and development of small molecule, tumor-agnostic therapies targeting p53. The company was founded by Arnold J. Levine, David Henry Mac, and Thomas E. Shenk in March 2013 and is headquartered in Princeton, NJ.

Employees54
IPOSep 25, 2020
Beta1.52
ATR, 14d0.10
Rel volume0.23
Short float3.06%
Insider own6.90%
Inst own44.51%

Snapshot

6 groups

Valuation

Index-
Market Cap95.15M
Enterprise Value-7.27M
Income-88.53M
Sales0.00M
Book/sh0.76
Cash/sh1.36
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees54
IPOSep 25, 2020

Ratios

P/E-
Forward P/E-
PEG-
P/S-
P/B1.67
P/C0.93
P/FCF-
EV/EBITDA-
EV/Sales-
Quick Ratio9.81
Current Ratio9.81
Debt/Eq0.00
LT Debt/Eq0.00
Option/ShortYes / Yes

Earnings

EPS (ttm)-1.53
EPS next Y-0.88
EPS next Q-0.27
EPS this Y8.78%
EPS next Y35.19%
EPS next 5Y24.38%
EPS past 3/5Y2.74% -13.98%
Sales past 3/5Y- -
EPS Y/Y TTM3.11%
Sales Y/Y TTM-
EPS Q/Q-30.60%
Sales Q/Q-
EarningsNov 10 BMO
EPS/Sales Surpr.-54.44% -

Ownership

Insider Own6.90%
Insider Trans0.00%
Inst Own44.51%
Inst Trans-3.85%
ROA-72.20%
ROE-99.42%
ROIC-155.03%
Gross Margin-
Oper. Margin-
Profit Margin-
SMA20-2.48%
SMA50-9.11%
SMA200-3.61%
Trades-

Technical

Shs Outstand75.53M
Shs Float70.30M
Short Float3.06%
Short Ratio3.20
Short Interest2.15M
52W High1.91 -34.03%
52W Low1.02 23.53%
Volatility7.12% 8.48%
ATR (14)0.10
RSI (14)45.39
Beta1.52
Rel Volume0.23
Avg Volume673.77K
Volume154,076

Performance

Perf Week-4.91%
Perf Month-6.67%
Perf Quarter3.70%
Perf Half Y-2.33%
Perf YTD0.80%
Perf Year-5.26%
Perf 3Y-37.00%
Perf 5Y-94.68%
Perf 10Y-
Recom1.00
Target Price4.00
Prev Close1.22
Price1.26
Change %3.28%

Analyst ratings

latest 10 of 14
DateActionAnalystRating changeTargetImplied
Jul 08, 2026InitiatedLLadenburg ThalmannBuy$3+138.1%
Nov 08, 2024UpgradeOOppenheimerPerform → Outperform$6+376.2%
May 13, 2024InitiatedCCraig HallumBuy$6+376.2%
Apr 12, 2024InitiatedJJefferiesBuy$5+296.8%
Dec 27, 2023InitiatedLLadenburg ThalmannBuy$7+455.6%
Mar 02, 2022UpgradeOOppenheimerPerform → Outperform$30+2,281.0%
Sep 22, 2021UpgradeGGoldmanNeutral → Buy$35 → $43+3,312.7%
Aug 19, 2021InitiatedOOppenheimerPerform
Aug 02, 2021InitiatedGGuggenheimBuy$56+4,344.4%
Jul 29, 2021InitiatedHH.C. WainwrightBuy$63+4,900.0%

Peers

Mkt cap
TickerCompanyMkt cap
BDTXBlack Diamond Therapeutics Inc92.50M
APREAprea Therapeutics Inc6.30M
ZNTLZentalis Pharmaceuticals Inc185.72M
KURAKura Oncology Inc687.66M
FHTXFoghorn Therapeutics Inc125.32M
TNGXTango Therapeutics Inc4.36B
RLAYRelay Therapeutics Inc4.36B
IDYAIdeaya Biosciences Inc3.16B
ERASErasca Inc5.88B
VSTMVerastem Inc1.15B

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
VXFVanguard Extended Market Index ETFAUM: 30.47B
IWCiShares Micro-Cap ETFAUM: 1.22B
BUSMEA Bridgeway Ultra-Small Company Market ETFAUM: 111.21M
AVTMAvantis Total Equity Markets ETFAUM: 758.92M

News

latest 14 of 200
  • PMV Pharmaceuticals Reports Third Quarter 2026 Financial Results and Corporate Highlights (GlobeNewswire)
  • Pivotal Phase 2 Rezatapopt PYNNACLE Data to Be Featured in Late-Breaking Oral Presentation at ENA 2026 (GlobeNewswire)
  • PMV Pharmaceuticals Appoints Matt Eckler, Ph.D., to Board of Directors (GlobeNewswire)
  • PMV Pharmaceuticals Appoints Philip Herman as Chief Commercial Officer (GlobeNewswire)
  • PMV Pharma Announces Pricing of Oversubscribed $50 Million Public Offering of Securities (GlobeNewswire) +6.61%
  • PMV Pharma Announces Proposed Public Offering of Securities (GlobeNewswire)
  • PMV Pharmaceuticals Announces Updated Promising Rezatapopt Monotherapy Interim Ovarian Cancer Data From PYNNACLE Phase 2 Pivotal Trial (GlobeNewswire)
  • PMV Pharmaceuticals Reports Second Quarter 2026 Financial Results and Corporate Highlights (GlobeNewswire)
  • PMV Pharmaceuticals Reports First Quarter 2026 Financial Results and Corporate Highlights (GlobeNewswire)
  • PMV Pharmaceuticals Announces Board Chair Transition (GlobeNewswire)
  • PMV Pharmaceuticals Reports Full Year 2025 Financial Results and Corporate Highlights (GlobeNewswire) +7.19%
  • New England Journal of Medicine Publishes First-in-Human Rezatapopt Data Showing Selective Reactivation of Mutant p53 in Advanced Solid Tumors (GlobeNewswire) +22.32%
  • PMV Pharmaceuticals Reports Third Quarter 2025 Financial Results and Corporate Highlights (GlobeNewswire) +6.77%
  • PMV Pharmaceuticals Announces Updated Rezatapopt Monotherapy Interim Data From Ongoing PYNNACLE Phase 2 Trial Across Multiple Solid Tumors With a TP53 Y220C Mutation (GlobeNewswire)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-10-0.520-0.337-0.5200.000.003
2026Q22026-08-14-0.340-0.388-0.3390.000.004
2026Q12026-05-12-0.340-0.410-0.3380.000.003
2025Q42026-03-06-0.330-0.395-0.3390.000.004
2025Q32025-11-12-0.400-0.403-0.3970.000.004
2025Q22025-08-07-0.410-0.383-0.4080.000.003
2025Q12025-05-09-0.340-0.373-0.3360.000.004
2024Q42025-03-03-0.450-0.388-0.4430.000.005
2024Q32024-11-07-0.370-0.346-0.3730.000.007
2024Q22024-08-08-0.020-0.350-0.0240.000.006
2024Q12024-05-09-0.300-0.360-0.2970.000.006
2023Q42024-02-29-0.300-0.370-0.3060.000.005
2023Q32023-11-09-0.340-0.463-0.3390.000.007
2023Q22023-08-09-0.380-0.486-0.3810.000.007
2023Q12023-05-10-0.420-0.457-0.4180.000.007
2022Q42023-03-02-0.420-0.431-0.4230.000.007

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2020FY-2.400-2.058-0.7690.000.03
2021FY-1.280-1.200-1.2820.000.00
2022FY-1.610-1.604-1.6080.000.00
2023FY-1.440-1.468-1.4360.000.00
2024FY-1.140-1.265-1.1380.000.00
2025FY-1.480-1.515-1.4800.000.00
2026FY--1.350--0.00
2027FY--0.875--4.78
2028FY--0.640--31.54
2029FY--0.427--56.21
2030FY-0.200--110.97

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-11-103000.000.000.00
2026Q4S2026-09-042000.000.000.00
2026Q4S2026-08-141000.000.000.00
2026Q4S2026-05-301000.000.000.00
2026Q4S2026-05-122000.000.000.00
2026Q4S2026-03-062000.000.000.00
2026Q4S2026-02-192000.000.000.00
2026Q4S2025-11-121000.000.000.00
2026Q4S2025-11-111000.000.000.00
2026Q4S2025-11-101000.000.000.00
2026Q4R2026-11-10300-0.30-0.34-0.24
2026Q4R2026-10-28200-0.29-0.34-0.24
2026Q4R2026-08-20201-0.29-0.34-0.24
2026Q4R2026-08-14301-0.34-0.43-0.24

Estimate history

EPS, annual-0.408-0.59-0.769-1.282-1.608-1.436-1.138-1.48-1.5345
Period20182019202020212022202320242025TTM
EPS, quarterly-0.373-0.443-0.336-0.408-0.397-0.339-0.338-0.339-0.519
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual000000000
Period20182019202020212022202320242025TTM
Sales, quarterly000000000
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual42.99942.99944.77845.43445.77151.44651.93553.33275.535
Period20182019202020212022202320242025MRQ
Shares, quarterly51.7551.93551.95452.99352.99353.33253.33253.4675.535
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue0.000.000.000.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.110.131.141.260.651.280.320.390.34
Gross Profit-0.11-0.13-1.14-1.26-0.65-1.28-0.32-0.39-0.34
Selling, General and Administrative Excl. Other77.0986.0784.3078.8876.3957.0134.6226.2518.55
Research and Development61.7869.7457.3854.6351.6736.1923.6120.7613.85
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-77.20-86.21-85.45-80.13-77.04-58.29-34.94-26.64-18.89
Interest Expense0.000.000.000.000.000.000.00--
Unusual Expense15.120.000.000.000.000.000.000.000.00
Net Income Before Taxes-88.51-79.91-74.81-68.96-73.33-57.82-34.43-25.34-17.54
Income Taxes0.02-2.17-16.100.00-0.010.020.010.010.00
Consolidated Net Income-88.53-77.74-58.71-68.96-73.32-57.85-34.44-25.35-17.54
Net Income From Continuing Operations-88.53-77.74-58.71-68.96-73.32-57.85-34.44-25.35-17.54
Net Income-88.53-77.74-58.71-68.96-73.32-57.85-34.44-25.35-17.54
EPS (Recurring)-1.18-1.48-1.14-1.44-1.61-1.28-0.77-0.59-0.41
EPS (Basic, Before Extraordinaries)-1.53-1.48-1.14-1.44-1.61-1.28-0.77-0.59-0.41
EPS (Diluted)-1.53-1.48-1.14-1.44-1.61-1.28-0.77-0.59-0.41
EBITDA-77.09-86.07-84.30-78.88-76.39-57.01-34.62-26.25-18.55
Non-Operating Income (Expense)3.826.2910.6411.173.710.470.511.291.36
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense4.664.687.019.788.053.901.410.660.85
Shares Outstanding75.5353.3351.9451.4545.7745.4344.7843.0043.00
Market Capitalization92.1392.1378.14158.59397.291,048.292,754.032,526.58-

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue0.000.000.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.020.020.030.030.030.030.040.04
Gross Profit-0.02-0.02-0.03-0.03-0.03-0.03-0.04-0.04
Selling, General and Administrative Excl. Other20.0418.8618.9819.2122.4922.8521.5325.13
Research and Development16.0414.6515.3015.7918.1818.3717.4013.73
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-20.06-18.88-19.02-19.24-22.52-22.88-21.56-25.17
Interest Expense0.000.000.000.000.000.000.000.00
Unusual Expense15.120.000.000.000.000.000.000.00
Net Income Before Taxes-34.38-18.08-18.04-18.01-21.07-21.20-19.63-23.00
Income Taxes-0.010.000.000.03-0.010.01-2.200.00
Consolidated Net Income-34.37-18.09-18.04-18.04-21.06-21.21-17.44-23.00
Net Income From Continuing Operations-34.37-18.09-18.04-18.04-21.06-21.21-17.44-23.00
Net Income-34.37-18.09-18.04-18.04-21.06-21.21-17.44-23.00
EPS (Recurring)-0.36-0.34-0.34-0.34-0.40-0.41-0.34-0.44
EPS (Basic, Before Extraordinaries)-0.52-0.34-0.34-0.34-0.40-0.41-0.34-0.44
EPS (Diluted)-0.52-0.34-0.34-0.34-0.40-0.41-0.34-0.44
EBITDA-20.04-18.86-18.98-19.21-22.49-22.85-21.53-25.13
Non-Operating Income (Expense)0.810.800.981.231.461.671.932.17
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense1.271.221.101.081.091.321.191.00
Shares Outstanding75.5353.4653.3353.3352.9952.9951.9551.94
Market Capitalization92.1371.4666.1366.5174.1955.0756.6178.14

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Cash & Short Term Investments112.94169.45203.88241.88297.99361.42101.4961.91
Short Term Receivables0.000.000.000.000.000.000.000.00
Inventories0.000.000.000.000.000.000.000.00
Other Current Assets2.286.203.535.133.303.340.610.33
Total Current Assets115.23175.66207.41247.01301.29364.76102.0962.24
Net Property, Plant & Equipment1.041.5519.0520.4913.150.570.741.02
Total Investments and Advances0.0013.8425.502.5016.910.000.000.00
Other Assets0.300.230.190.310.220.200.200.20
Total Assets116.56191.29252.15270.31331.57365.53103.0363.46
Short Term Debt Incl. Current Port. of LT Debt0.400.350.850.530.400.000.000.00
Accounts Payable3.156.583.243.003.191.612.841.04
Other Current Liabilities7.867.449.947.318.634.801.691.29
Total Current Liabilities11.4114.3714.0310.8312.226.414.522.33
Long Term Debt0.430.8412.4313.4510.790.00168.93107.23
Provision for Risks Charges0.000.000.000.000.000.000.000.00
Other Liabilities0.000.000.000.000.000.000.050.04
Total Liabilities11.8515.2126.4624.2823.016.41173.51109.60
Non-Equity Reserves0.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.00
Common Equity104.71176.08225.69246.03308.56359.12-70.47-46.14
Total Shareholders Equity104.71176.08225.69246.03308.56359.12-70.47-46.14
Accumulated Minority Interest0.000.000.000.000.000.000.000.00
Total Equity104.71176.08225.69246.03308.56359.12-70.47-46.14
Total Liabilities & Stockholders Equity116.56191.29252.15270.31331.57365.53103.0363.46
Book Value Per Share1.963.394.395.386.798.02-1.64-1.07
Tangible Book Value Per Share1.963.394.395.386.798.02-1.64-1.07
Full-Time Employees54476362544436-
Price to Book Ratio1.610.390.671.523.407.676.85-
Return on Assets-50.51-26.48-26.40-24.36-16.60-14.70-30.45-
Return on Equity-55.37-29.23-29.24-26.44-17.33-23.86--
Return on Invested Capital-73.94-33.18-28.96-28.26-18.11-9.59-25.75-28.71
Quick Ratio10.0912.2214.7822.8024.6656.9022.5726.75
Current Ratio10.0912.2214.7822.8024.6656.9022.5726.75

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-88.53-77.74-58.71-68.96-73.32-57.85-34.44-25.35-17.54
Depreciation0.110.131.141.260.651.280.320.390.34
Other Funds (Non Cash)19.263.127.886.629.475.872.230.981.39
Funds from Operations-69.16-74.49-49.69-61.08-63.19-50.69-31.89-23.99-15.81
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital-0.470.91-1.595.43-0.574.12-0.841.920.64
Cash from Operating Activities-69.63-73.58-51.28-55.66-63.76-46.57-32.74-22.07-15.18
Capital Expenditures-0.01-0.03-0.66-0.96-7.98-1.35-0.15-0.11-0.45
Net Assets From Acquisitions0.000.000.000.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.030.250.000.000.000.000.000.00
Purchase or Sale of Investments5.8670.1753.76-49.586.62-142.2428.063.3422.14
Purchase of Investments-99.61-88.20-148.29-220.54-229.20-256.85-14.51-43.45-48.68
Sale Or Maturity of Investments105.47158.37202.04170.96235.81114.6142.5746.7970.82
Other Uses0.000.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.000.00
Cash from Investing Activities5.8470.1753.35-50.55-1.37-143.5827.913.2321.69
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock47.440.510.3135.580.962.02292.9761.800.00
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.000.00
Sale of Common Pref Stock47.440.510.3135.580.962.02292.9761.800.00
Proceedsfrom Stock Options-3.860.000.0035.120.000.00292.9761.700.00
Issuance or Reduction of Debt, Net0.000.000.000.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.000.000.000.00
Cash from Financing Activities47.440.510.3135.580.962.02292.9761.800.00
Exchange Rate Effect0.000.01-0.040.03-----
Net Change in Cash-16.34-2.892.35-70.59-64.17-188.13288.1442.976.51
Free Cash Flow-69.64-73.61-51.94-56.62-71.74-47.92-32.89-22.17-15.63
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.000.00
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments102.5679.4393.55112.94129.25142.27
Short Term Receivables0.000.000.000.000.000.00
Inventories0.000.000.000.000.000.00
Other Current Assets2.331.982.232.283.203.04
Total Current Assets104.8981.4195.78115.23132.45145.31
Net Property, Plant & Equipment0.260.360.491.041.151.26
Total Investments and Advances5.960.000.000.000.006.03
Other Assets0.290.300.300.300.250.25
Total Assets111.4082.0796.56116.56133.84152.85
Short Term Debt Incl. Current Port. of LT Debt0.140.220.290.400.390.38
Accounts Payable1.642.021.633.153.402.60
Other Current Liabilities8.918.336.677.868.528.63
Total Current Liabilities10.6910.578.6011.4112.3011.61
Long Term Debt0.000.000.000.430.540.64
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities43.610.000.000.000.000.00
Total Liabilities54.3010.578.6011.8512.8512.25
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity57.1171.5087.97104.71121.00140.60
Total Shareholders Equity57.1171.5087.97104.71121.00140.60
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity57.1171.5087.97104.71121.00140.60
Total Liabilities & Stockholders Equity111.4082.0796.56116.56133.84152.85
Book Value Per Share0.761.341.651.962.282.65
Tangible Book Value Per Share0.761.341.651.962.282.65
Full-Time Employees---54--
Price to Book Ratio1.610.810.630.550.530.34
Return on Assets-72.20-64.04-58.65-50.51-46.29-41.43
Return on Equity-99.42-70.93-63.16-55.37-51.87-45.57
Return on Invested Capital-60.19-25.30-20.51-17.15-17.33-15.02
Quick Ratio9.817.7011.1410.0910.7612.52
Current Ratio9.817.7011.1410.0910.7612.52

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income-34.37-18.09-18.04-18.04-21.06-21.21
Depreciation0.020.020.030.030.030.03
Other Funds (Non Cash)16.301.180.980.800.690.96
Funds from Operations-18.05-16.88-17.02-17.20-20.34-20.22
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital-0.132.30-2.660.010.521.91
Cash from Operating Activities-18.18-14.58-19.68-17.19-19.82-18.30
Capital Expenditures0.000.000.00-0.010.00-0.01
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.03
Purchase or Sale of Investments-21.20-12.2320.8218.4612.0310.97
Purchase of Investments-41.16-26.73-10.68-21.04-20.47-30.96
Sale Or Maturity of Investments19.9614.5031.5039.5032.5041.93
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities-21.20-12.2320.8218.4412.0310.99
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock46.910.140.000.390.000.10
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock46.910.140.000.390.000.10
Proceedsfrom Stock Options-3.860.000.000.000.000.00
Issuance or Reduction of Debt, Net0.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities46.910.140.000.390.000.10
Exchange Rate Effect0.000.000.00-0.000.00-0.00
Net Change in Cash7.53-26.661.151.65-7.79-7.21
Free Cash Flow-18.18-14.58-19.68-17.20-19.82-18.31

Revenue breakdown

Revenue split-

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-303.06%2.2M70.3M677.92K
2026-10-153.25%2.3M70.3M652.75K
2026-09-304.10%2.8M68.2M551.84K
2026-09-154.28%2.9M68.2M479.44K
2026-08-313.27%2.3M69.3M309.03K
2026-08-144.58%2.2M49.0M318.74K
2026-07-314.86%2.4M48.9M335.77K
2026-07-154.95%2.4M48.9M359.50K
2026-06-305.95%2.9M48.9M370.90K
2026-06-155.87%2.9M48.9M380.17K
2026-05-296.66%3.3M48.9M588.93K
2026-05-156.30%3.1M48.9M674.25K
2026-04-305.39%2.6M48.9M641.28K
2026-04-154.74%2.3M48.9M643.40K
2026-03-313.56%1.6M43.9M601.57K
2026-03-133.38%1.5M43.9M570.85K
2026-02-272.81%1.2M43.9M362.05K
2026-02-133.43%1.5M43.8M263.61K
2026-01-304.23%1.9M43.8M264.30K
2026-01-154.10%1.8M43.8M358.73K

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call2.500.000.050.0113.2552.000.000.775-0.0410.001
call5.000.001.900.005.6110.000.000.127-0.0130.000
call7.500.001.900.006.6590.000.000.114-0.0140.000
put2.500.002.550.000.0000.000.00-0.831-0.0100.000
put5.002.505.100.000.0000.000.00-0.873-0.0120.000
put7.505.007.600.000.0000.000.00-0.886-0.0130.000

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-1010-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-11-108-KCurrent report2026-11-10SEC
2026-10-054Statement of changes in beneficial ownership of securities2026-10-01SEC
2026-10-053Initial statement of beneficial ownership of securities2026-10-01SEC
2026-10-058-KCurrent report2026-10-01SEC
2026-09-15SCHEDULE 13GSEC
2026-09-028-KCurrent report2026-08-31SEC
2026-09-02424B5SEC
2026-08-31424B3SEC
2026-08-31424B5SEC
2026-08-318-KCurrent report2026-08-31SEC
2026-08-1410-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-148-KCurrent report2026-08-14SEC
2026-07-28SCHEDULE 13G/ASEC
2026-07-10SCHEDULE 13G/ASEC
2026-06-054Statement of changes in beneficial ownership of securities2026-06-04SEC
2026-06-054Statement of changes in beneficial ownership of securities2026-06-04SEC
2026-06-054Statement of changes in beneficial ownership of securities2026-06-04SEC
2026-06-054Statement of changes in beneficial ownership of securities2026-06-04SEC
2026-06-058-KCurrent report2026-06-04SEC
2026-06-054Statement of changes in beneficial ownership of securities2026-06-04SEC
2026-05-15SCHEDULE 13G/ASEC
2026-05-1210-QQuarterly report pursuant to Section 13 or 15(d)2026-03-31SEC
2026-05-128-KCurrent report2026-05-12SEC
2026-05-04SCHEDULE 13G/ASEC
2026-04-22ARSAnnual report to security holders. 2025-12-31SEC
2026-04-22DEFA14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934SEC
2026-04-22DEF 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-06-04SEC
2026-03-094Statement of changes in beneficial ownership of securities2026-03-05SEC
2026-03-094Statement of changes in beneficial ownership of securities2026-03-05SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
BML Capital Management, LLC9.71%
TANG CAPITAL MANAGEMENT LLC7.96%
Sio Capital Management, LLC4.94%
Euclidean Capital LLC4.93%
ADAGE CAPITAL PARTNERS GP, L.L.C.4.43%
VANGUARD CAPITAL MANAGEMENT LLC3.77%
ArrowMark Colorado Holdings LLC3.67%
TWO SIGMA INVESTMENTS, LP3.66%
Eversept Partners, LP3.55%
ACADIAN ASSET MANAGEMENT LLC3.03%

Funds

Fund% owned
VANGUARD TOTAL STOCK MARKET INDEX FUND2.79%
Meridian Small Cap Growth Fund1.98%
VANGUARD EXTENDED MARKET INDEX FUND0.85%
Ultra-Small Company Fund0.62%
Fidelity Extended Market Index Fund0.40%
iShares Micro-Cap ETF0.30%
Goldman Sachs Absolute Return Tracker Fund0.25%
Ultra-Small Company Market Fund0.14%
Fidelity Total Market Index Fund0.13%
Fidelity Series Total Market Index Fund0.11%

OakChart. PMVP. Cached 15 minutes.

Some panels did not load: insider.